See how the invention of the first antihistamine eye drops sparked a journey of discovery focused on challenging eye diseases.
Blindness and vision loss impact over 1 billion people around the world. From our first discovery in 1948 at Allergan, now part of AbbVie, our scientists have pioneered research on ocular diseases and treatment for the front and back of the eye. Today we're building on our already broad and diverse portfolio with a focus on neurodegenerative diseases of the retina and ocular surface diseases. We're investigating the genetic basis for certain diseases to help us bring forward innovative medicines to reduce the treatment burden for patients.
Each year more people will receive a vision-threatening diagnosis due to aging and lifestyle factors. Our robust research and development approach is anchored in improving the standards of care across multiple disease areas to make a meaningful difference for patients.
Our research, focused on unmet needs, fuels an innovative pipeline of treatments that seek to preserve and protect vision and prevent blindness. Our research interests include:
Improving standards for all
Bridging our understanding of biological processes and the genetic basis of human disease to accelerate ophthalmic drug discovery.
Finding new approaches
Leading innovation in long-acting therapeutic approaches via mechanism of action, sustained-release formulations or gene therapy to reduce the treatment burden.
Collaboration in innovation
Working with colleagues across AbbVie to seize the scientific opportunity of innovation within oncology, immunology and neuroscience through knowledge of common disease pathways.
State-of-the-art imagery
Applying state-of-the-art imaging modalities to monitor disease progression and therapeutic intervention to accelerate the translation of bench science to the clinic.
Strategic collaboration
Joining forces with innovative partners that complement our strengths, capabilities and commitments to eye care, including our work in chronic retinal diseases with REGENXBIO.
We are focused on some of the most challenging eye diseases, including:
Explore our career opportunities.
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?